Estrogens of multiple classes and their role in mental health disease mechanisms

International Journal of Women's Health

Volumn 2, Issue 1, 2010, Pages 153-166

  Watson, Cheryl S ^a   Alyea, Rebecca A ^a   Cunningham, Kathryn A ^a   Jeng, Yow Jiun ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Brain function; Estrogen receptor ; Estrogen receptor ; GPER; GPR30; Neurotransmitter receptors; Phytoestrogens; Transporters; Xenoestrogens

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHYLENE; 4,4' ISOPROPYLIDENEDIPHENOL; CARRIER PROTEIN; CONJUGATED ESTROGEN; COUMESTROL; DIELDRIN; DIETHYLSTILBESTROL; ENDOSULFAN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; LIGAND; MONOAMINE; NEUROTRANSMITTER; NONYLPHENOL; PHYTOESTROGEN; RECEPTOR SUBTYPE; SEX HORMONE;

BEHAVIOR; BRAIN DAMAGE; BRAIN FUNCTION; CELLULAR DISTRIBUTION; COGNITION; COGNITIVE DEVELOPMENT; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; DRUG MEGADOSE; DRUG STRUCTURE; GENDER; GENETIC REGULATION; HUMAN; LIFE CYCLE; MENTAL DISEASE; MENTAL HEALTH; MOOD; NERVE CELL; PATHOPHYSIOLOGY; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 77955542861     PISSN: None     EISSN: 11791411     Source Type: Book Series    
DOI: 10.2147/ijwh.s6907     Document Type: Review

References (227)

1. Micevych P, Dominguez R. Membrane estradiol signaling in the brain. Front Neuroendocrinol. 2009;30:315-327.
2. Pfaff D. Hormone-driven mechanisms in the central nervous system facilitate the analysis of mammalian behaviours. J Endocrinol. 2005; 184:447-453.
3. Mora S, Dussaubat N, Diaz-Veliz G. Effects of the estrous cycle and ovarian hormones on behavioral indices of anxiety in female rats. Psychoneuroendocrinology. 1996;21:609-620.
4. Sell SL, Scalzitti JM, Thomas ML, Cunningham KA. Influence of ovarian hormones and estrous cycle on the behavioral response to cocaine in female rats. J Pharmacol Exp Ther. 2000;293:879-886.
5. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protocols. 2007;2:322-328.
6. Belcher SM, Ma X, Le HH. Blockade of estrogen receptor signaling inhibits growth and migration of medulloblastoma. Endocr. 2009;150: 1112-1121.
7. Jackson LR, Robinson TE, Becker JB. Sex differences and hormonal influences on acquisition of cocaine self-administration in rats. Neuropsychopharmacology. 2006;31:129-138.
8. Fahrbach SE, Meisel RL, Pfaff DW. Preoptic implants of estradiol increase wheel running but not the open field activity of female rats. Physiol Behav. 1985;35:985-992.
9. Walf AA, Frye CA. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology. 2006;31:1097-1111.
10. Belcher SM. Rapid signaling mechanisms of estrogens in the developing cerebellum. Brain Res Rev. 2008;57:481-492.
11. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-a and -ß mRNA in the rat central nervous system. J Comp Neurol. 1997;388:507-525.
12. Qiu J, Ronnekleiv OK, Kelly MJ. Modulation of hypothalamic neuronal activity through a novel G-protein-coupled estrogen membrane receptor. Steroids. 2008;73:985-991.
13. Brailoiu E, Dun SL, Brailoiu GC, et al. Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J Endocrinol. 2007;193:311-321.
14. Hazell GG, Yao ST, Roper JA, Prossnitz ER, O'Carroll AM, Lolait SJ. Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. J Endocrinol. 2009;202:223-236.
15. Staley JK, Sanacora G, Tamagnan G, et al. Sex differences in diencephalon serotonin transporter availability in major depression. Biol Psychiatry. 2006;59:40-47.
16. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 2001;15:797-817.
17. Felthous AR, Robinson DB. Oral contraceptive medication in prevention of psychotic exacerbations associated with phases of the menstrual cycle. J Prev Psychiatry. 1981;1:5-14.
18. Parker WH, Shoupe D, Broder MS, Liu Z, Farquhar C, Berek JS. Elective oophorectomy in the gynecological patient: when is it desirable? Curr Opin Obstet Gynecol. 2007;19:350-354.
19. Dluzen DE, Mickley KR. Gender differences in modulatory effects of tamoxifen upon the nigrostriatal dopaminergic system. Pharmacol Biochem Behav. 2005;80:27-33.
20. Foltynie T, Lewis SG, Goldberg TE, et al. The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol. 2005;252:833-838.
21. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord. 2001;16:830-837.
22. Quinn PO. Treating adolescent girls and women with ADHD: gender-specific issues. J Clin Psychol. 2005;61:579-587.
23. Kurlan R. The pathogenesis of Tourette's syndrome. A possible role for hormonal and excitatory neurotransmitter influences in brain development. Arch Neurol. 1992;49:874-876.
24. Yoon DY, Rippel CA, Kobets AJ, et al. Dopaminergic polymorphisms in Tourette syndrome: Association with the DAT gene (SLC6A3). Am J Med Genet B Neuropsychiatr Genet. 2007;144:605-610.
25. Compton J, van AT, Murphy D. Mood, cognition and Alzheimer's disease. Best Pract Res Clin Obstet Gynaecol. 2002;16:357-370.
26. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006;16: 687-698.
27. Osterlund MK, Overstreet DH, Hurd YL. The flinders sensitive line rats, a genetic model of depression, show abnormal serotonin receptor mRNA expression in the brain that is reversed by 17ß-estradiol. Brain Res Mol Brain Res. 1999;74:158-166.
28. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69 Suppl E1:4-7.
29. Doornbos B, Fokkema DS, Molhoek M, Tanke MA, Postema F, Korf J. Abrupt rather than gradual hormonal changes induce postpartum blues-like behavior in rats. Life Sci. 2009;84:69-74.
30. Williams CL. Estrogen effects on cognition across the lifespan. Horm Behav. 1998;34:80-84.
31. Moses-Kolko EL, Berga SL, Kalro B, Sit DK, Wisner KL. Transdermal estradiol for postpartum depression: a promising treatment option. Clin Obstet Gynecol. 2009;52:516-529.
32. Loucks TL, Berga SL. Does postmenopausal estrogen use confer neuroprotection? Semin Reprod Med. 2009;27:260-274.
33. Prior JC. Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine. 2005; 26:297-300.
34. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder. Obstet Gynecol. 2005;106:492-501.
35. Almeida OP, Barclay L. Sex hormones and their impact on dementia and depression: a clinical perspective. Expert Opin Pharmacother. 2001; 2:527-535.
36. Stein D, Hanukoglu A, Blank S, Elizur A. Cyclic psychosis associated with the menstrual cycle. Br J Psychiatry. 1993;163:824-828.
37. Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. J Affect Disord. 2003;74:67-83.
38. Taylor M. Psychological consequences of surgical menopause. J Reprod Med. 2001;46:317-324.
39. Oinonen KA, Mazmanian D. Does body fat protect against negative moods in women? Med Hypotheses. 2001;57:387-388.
40. Dreher JC, Schmidt PJ, Kohn P, Furman D, Rubinow D, Berman KF. Menstrual cycle phase modulates reward-related neural function in women. Proc Natl Acad Sci U S A. 2007;104:2465-2470.
41. Sell SL, Thomas ML, Cunningham KA. Influence of estrous cycle and estradiol on behavioral sensitization to cocaine in female rats. Drug Alcohol Depend. 2002;67:281-290.
42. Elman I, Karlsgodt KH, Gastfriend DR. Gender differences in cocaine craving among non-treatment-seeking individuals with cocaine dependence. Am J Drug Alcohol Abuse. 2001;27:193-202.
43. Soares CN, Poitras JR, Prouty J. Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs Aging. 2003;20:85-100.
44. Coromina SM, Rodie JU, de Montagut LM, Sanchez AM. The use of oral contraceptives as a prevention of recurrent premenstrual psychosis. Psychiatry Res. 2009;170:290-291.
45. Benmansour S, Piotrowski JP, Altamirano AV, Frazer A. Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. Neuropsychopharmacology. 2009;34:555-564.
46. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15:422-430.
47. Shively CA, Bethea CL. Cognition, mood disorders, and sex hormones. ILAR J. 2004;45:189-199.
48. Klier CM, Muzik M, Dervic K, et al. The role of estrogen and progesterone in depression after birth. J Psychiatr Res. 2007;41:273-279.
49. Genazzani AR, Spinetti A, Gallo R, Bernardi F. Menopause and the central nervous system: intervention options. Maturitas. 1999;31:103-110.
50. Grigoriadis S, Kennedy SH. Role of estrogen in the treatment of depression. Am J Ther. 2002;9:503-509.
51. Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med. 1999;61:676-697.
52. Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000;157:924-930.
53. Morrison MF, Kallan MJ, Ten HT, Katz I, Tweedy K, Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. 2004;55:406-412.
54. Huttner RP, Shepherd JE. Gonadal steroids, selective serotonin reuptake inhibitors, and mood disorders in women. Med Clin North Am. 2003;87:1065-1076.
55. Miller KJ. The other side of estrogen replacement therapy: outcome study results of mood improvement in estrogen users and nonusers. Curr Psychiatry Rep. 2003;5:439-444.
56. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. 1979;36:550-554.
57. Watson CS, Jeng YJ, Kochukov MY. Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation. FASEB J. 2008;22:3328-3336.
58. Alyea RA, Watson CS. Nongenomic mechanisms of physiological estrogen-mediated dopamine efflux. BMC Neurosci. 2009;10:59.
59. Lebrun CE, van der Schouw YT, De Jong FH, Pols HA, Grobbee DE, Lamberts SW. Endogenous oestrogens are related to cognition in healthy elderly women. Clin Endocrinol (Oxf). 2005;63:50-55.
60. Almeida OP, Lautenschlager N, Vasikaram S, Leedman P, Flicker L. Association between physiological serum concentration of estrogen and the mental health of community-dwelling postmenopausal women age 70 years and over. Am J Geriatr Psychiatry. 2005;13:142-149.
61. Barha CK, Galea LA. Influence of different estrogens on neuroplasticity and cognition in the hippocampus. Biochim Biophys Acta. 2010; S0304-4165(10):00011-00015.
62. Newby D, Aitken DA, Howatson AG, Connor JM. Placental synthesis of oestriol in Down's syndrome pregnancies. Placenta. 2000;21:263-267.
63. Vanson A, Arnold AP, Schlinger BA. 3 ß-hydroxysteroid dehydrogenase/isomerase and aromatase activity in primary cultures of developing zebra finch telencephalon: dehydroepiandrosterone as substrate for synthesis of androstenedione and estrogens. Gen Comp Endocrinol. 1996;102:342-350.
64. Reddy VV. Estriol synthesis in rat brain and pituitary. Brain Res. 1979;175:165-168.
65. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab. 1985;61:564-570.
66. Richardson TA, Robinson RD. Menopause and depression: a review of psychologic function and sex steroid neurobiology during the menopause(1). Prim Care Update Ob Gyns. 2000;7:215-223.
67. Moffatt CA, Rissman EF, Shupnik MA, Blaustein JD. Induction of progestin receptors by estradiol in the forebrain of estrogen receptor-a gene-disrupted mice. J Neurosci. 1998;18:9556-9563.
68. Dannies PS. Control of prolactin production by estrogen. In: Litwack G, ed. Biochemical Actions of Hormones. 12 ed. Orlando: Academic Press, Inc.; 1985;289-310.
69. Sobrinho LG. Prolactin, psychological stress and environment in humans: adaptation and maladaptation. Pituitary. 2003;6:35-39.
70. Bression D, Brandi AM. In vitro and in vivo antagonistic regulation by estradiol and progesterone of the rat pituitary domperidone binding sites: correlation with ovarian steroid regulation of the dopaminergic inhibition of prolactin secretion in vitro. Endocr. 1985;116:1905.
71. Arbogast LA, Voogt JL. Hyperprolactinemia increases and hypoprolactinemia decreases tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nuclei, but not the substantia nigra or zona incerta. Endocr. 1991;128:997-1005.
72. van Amelsvoort TA, Abel KM, Robertson DM, et al. Prolactin response to d-fenfluramine in postmenopausal women on and off ERT: comparison with young women. Psychoneuroendocrinology. 2001;26:493-502.
73. Adams AB. Human breast cancer: concerted role of diet, prolactin and adrenal C19-delta 5 steroids in tumorigenesis. Int J Cancer. 1992;50:854-858.
74. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest. 1997;99:618-627.
75. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24:1-27.
76. Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor a and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol. 2004;88:69-77.
77. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERa-positive and ERa-negative mammary cancer in transgenic mice. Oncogene. 2003;22:4664-4674.
78. Gorski J, Wendell D, Gregg D, Chun TY. Estrogens and the genetic control of tumor growth. [Review] [23 refs]. Prog Clin Bio Res. 1997;396:233-243.
79. Lee KC, Lee KW. Nuclear receptors, coactivators and chromatin: new approaches, new insights. Trends Endocrinol Metab. 2001;12: 191-197.
80. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/ thyroid receptor superfamily members. [Review]. Ann Rev Biochem. 1994;63:451-486.
81. Evans RM. The steroid and thyroid hormone receptor superfamily [Review]. Science. 1988;240:889-895.
82. Bulayeva NN, Gametchu B, Watson CS. Quantitative measurement of estrogen-induced ERK 1 and 2 activation via multiple membraneinitiated signaling pathways. Steroids. 2004;69:181-192.
83. Campbell CH, Bulayeva N, Brown DB, Gametchu B, Watson CS. Regulation of the membrane estrogen receptor-a: role of cell density, serum, cell passage number, and estradiol. FASEB J. 2002; 16:1917-1927.
84. Clarke CH, Norfleet AM, Clarke MSF., Watson CS, Cunningham KA, Thomas ML. Peri-membrane localization of the estrogen receptor-a protein in neuronal processes of cultured hippocampal neurons. Neuroendocrinology. 2000;71:34-42.
85. Norfleet AM, Clarke C, Gametchu B, Watson CS. Antibodies to the estrogen receptor-a modulate prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors. FASEB J. 2000;14:157-165.
86. Norfleet AM, Thomas ML, Gametchu B, Watson CS. Estrogen receptor-a detected on the plasma membrane of aldehyde-fixed GH3/ B6/F10 rat pituitary cells by enzyme-linked immunocytochemistry. Endocr. 1999;140:3805-3814.
87. Pappas TC, Gametchu B, Yannariello-Brown J, Collins TJ, Watson CS. Membrane estrogen receptors in GH3/B6 cells are associated with rapid estrogen-induced release of prolactin. Endocrine. 1994;2:813-822.
88. Pappas TC, Gametchu B, Watson CS. Membrane estrogen receptorenriched GH3/B6 cells have an enhanced non-genomic response to estrogen. Endocrine. 1995;3:743-749.
89. Pappas TC, Gametchu B, Watson CS. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 1995;9:404-410.
90. Szego CM. Cytostructural correlates of hormone action: new common ground in receptor-mediated signal propagation for steroid and peptide agonists. Endocrine. 1994;2:1079-1093.
91. Watson CS. The Identities of Membrane Steroid Receptors.... and Other Proteins Mediating Nongenomic Steroid Action. Boston: Kluwer Academic Publishers, 2003.
92. Watson CS, Gametchu B. Proteins of multiple classes participate in nongenomic steroid actions. Exp Biol Med. 2003;228:1272-1281.
93. Watson CS, Gametchu B. Membrane-initiated steroid actions and the proteins that mediate them. Proc Soc Exp Biol Med. 1999;220:9-19.
94. Watson CS. Signaling themes shared between peptide and steroid hormones at the plasma membrane [Review] STKE E1. Science's Signal Transduction Knowledge Environment. [serial online] 1999.
95. Ikeda Y, Nagai A, Ikeda MA, Hayashi S. Sexually dimorphic and estrogen-dependent expression of estrogen receptor ß in the ventromedial hypothalamus during rat postnatal development. Endocr. 2003;144:5098-5104.
96. Morissette M, Le SM, D'Astous M, et al. Contribution of estrogen receptors a and ß to the effects of estradiol in the brain. J Steroid Biochem Mol Biol. 2008;108:327-338.
97. Waters EM, Mitterling K, Spencer JL, Mazid S, McEwen BS, Milner TA. Estrogen receptor a and ß specific agonists regulate expression of synaptic proteins in rat hippocampus. Brain Res. 2009; 1290:1-11.
98. Gonzales KL, Tetel MJ, Wagner CK. Estrogen receptor (ER) ß modulates ERa responses to estrogens in the developing rat ventromedial nucleus of the hypothalamus. Endocr. 2008;149:4615-4621.
99. Le SM, Di PT. Influence of oestrogenic compounds on monoamine transporters in rat striatum. J Neuroendocrinol. 2006;18:25-32.
100. D'Astous M, Mendez P, Morissette M, Garcia-Segura LM, Di PT. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol Pharmacol. 2006;69:1492-1498.
101. Lacreuse A, Wilson ME, Herndon JG. No effect of different estrogen receptor ligands on cognition in adult female monkeys. Physiol Behav. 2009;96:448-456.
102. Walf AA, Koonce CJ, Frye CA. Estradiol or diarylpropionitrile administration to wild type, but not estrogen receptor ß knockout, mice enhances performance in the object recognition and object placement tasks. Neurobiol Learn Mem. 2008;89:513-521.
103. Alyea RA, Laurence SE, Kim SH, Katzenellenbogen BS, Katzenellenbogen JA, Watson CS. The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC-12 cells. J Neurochem. 2008;106:1525-1533.
104. Koldzic-Zivanovic N, Seitz PK, Watson CS, Cunningham KA, Thomas ML. Intracellular signaling involved in estrogen regulation of serotonin reuptake. Mol Cell Endocrinol. 2004;226:33-42.
105. Watson CS, Pappas TC, Gametchu B. The other estrogen receptor in the plasma membrane: implications for the actions of environmental estrogens. Environ Health Perspect. 1995;103 Suppl 7:41-50.
106. Filardo EJ, Quinn JA, Bland KI, Frackelton AR. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000;14:1649-1660.
107. Filardo EJ, Quinn JA, Frackelton AR, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 2002;16:70-84.
108. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625-1630.
109. Xu H, Qin S, Carrasco GA, et al. Extra-nuclear estrogen receptor GPR30 regulates serotonin function in rat hypothalamus. Neuroscience. 2009;158:1599-1607.
110. Watson CS, Alyea RA, Hawkins BE, Thomas ML, Cunningham KA, Jakubas AA. Estradiol effects on the dopamine transporter - protein levels, subcellular location, and function. J Mol Signal. 2006;1:5.
111. Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;2:207-212.
112. Ariazi EA, Brailoiu E, Yerrum S, et al. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010;70:1184-1194.
113. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005;66:974-981.
114. Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol. 2005;204:355-360.
115. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci. 2003;4:13-25.
116. Giros B, Caron MG. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci. 1993;14:43-49.
117. Blakely RD, Bauman AL. Biogenic amine transporters: regulation in flux. Curr Opin Neurobiol. 2000;10:328-336.
118. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E. Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature. 2005;437:215-223.
119. Pifl C, Drobny H, Reither H, Hornykiewicz O, Singer EA. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol. 1995;47:368-373.
120. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci. 2001;21:1413-1419.
121. Kokoshka JM, Vaughan RA, Hanson GR, Fleckenstein AE. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol. 1998;361:269-275.
122. Holton KL, Loder MK, Melikian HE. Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization - on line in press. Nat Neurosci. 2005;8:881-888.
123. Jayanthi LD, Samuvel DJ, Blakely RD, Ramamoorthy S. Evidence for biphasic effects of protein kinase C on serotonin transporter function, endocytosis, and phosphorylation. Mol Pharmacol. 2005;67: 2077-2087.
124. Ramamoorthy S, Blakely RD. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science. 1999;285:763-766.
125. Melikian HE. Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation. Pharmacol Ther. 2004;104:17-27.
126. Gulley JM, Doolen S, Zahniser NR. Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J Neurochem. 2002;83:400-411.
127. Prasad HC, Steiner JA, Sutcliffe JS, Blakely RD. Enhanced activity of human serotonin transporter variants associated with autism. Philos Trans R Soc Lond B Biol Sci. 2009;364:163-173.
128. Eriksen J, Rasmussen SG, Rasmussen TN, et al. Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs. J Neurosci. 2009;29:6794-6808.
129. Jeng YJ, Kochukov MY, Watson CS. Membrane estrogen receptor-a-mediated nongenomic actions of phytoestrogens in GH3/ B6/F10 pituitary tumor cells. J Mol Signal. 2009;4:2.
130. Jeng YJ, Watson CS. Proliferative and anti-proliferative effects of dietary levels of phytoestrogens in rat pituitary GH3/B6/F10 cells - the involvement of rapidly activated kinases and caspases. BMC Cancer. 2009;9:334.
131. Watson CS. Signaling themes shared between peptide and steroid hormones at the plasma membrane. Sci STKE. 1999;1999:E1.
132. Foster JD, Adkins SD, Lever JR, Vaughan RA. Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J Neurochem. 2008;105:1683-1699.
133. Gorentla BK, Moritz AE, Foster JD, Vaughan RA. Proline-directed phosphorylation of the dopamine transporter N-terminal domain. Biochem. 2009;48:1067-1076.
134. Price DA, Sorkin A, Zahniser NR. Cyclin-dependent kinase 5 inhibitors: inhibition of dopamine transporter activity. Mol Pharmacol. 2009;76:812-823.
135. Eshleman AJ, Henningsen RA, Neve KA, Janowsky A. Release of dopamine via the human transporter. Mol Pharmacol. 1994;45:312-316.
136. Holton KL, Loder MK, Melikian HE. Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat Neurosci. 2005;8:881-888.
137. Torres GE, Carneiro A, Seamans K, et al. Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem. 2003;278:2731-2739.
138. Chambliss KL, Yuhanna IS, Mineo C, et al. Estrogen receptor a and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res. 2000;87:E44-E52.
139. Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor a variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A. 2003;100:4807-4812.
140. Zivadinovic D, Watson CS. Membrane estrogen receptor-a levels predict estrogen-induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res. 2005;7:R130-R144.
141. Smart EJ, Ying YS, Anderson RG. Hormonal regulation of caveolae internalization. J Cell Biol. 1995;131:929-938.
142. Mozley LH, Gur RC, Mozley PD, Gur RE. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry. 2001;158:1492-1499.
143. Munro CA, McCaul ME, Wong DF, et al. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry. 2006;59:966-974.
144. Evans SM. The role of estradiol and progesterone in modulating the subjective effects of stimulants in humans 1. Exp Clin Psychopharmacol. 2007;15:418-426.
145. White TL, Justice AJ, de WH. Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase 1. Pharmacol Biochem Behav. 2002;73:729-741.
146. Fog JU, Khoshbouei H, Holy M, et al. Calmodulin Kinase II Interacts with the Dopamine Transporter C Terminus to Regulate Amphetamine-Induced Reverse Transport. Neuron. 2006;51:417-429.
147. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annual Review of Pharmacology and Toxicology. 2007;47:681-698.
148. Alyea RA, Watson CS. Differential regulation of dopamine transporter function and location by low concentrations of environmental estrogens and 17ß-estradiol. Environ Health Perspect. 2009;117:778-783.
149. Furman CA, Chen R, Guptaroy B, Zhang M, Holz RW, Gnegy M. Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy. J Neurosci. 2009;29:3328-3336.
150. Boudanova E, Navaroli DM, Melikian HE. Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent. Neuropharmacology. 2008;54:605-612.
151. Belcher SM, Le HH, Spurling L, Wong JK. Rapid estrogenic regulation of extracellular signal-regulated kinase 1/2 signaling in cerebellar granule cells involves a G protein-and protein kinase A-dependent mechanism and intracellular activation of protein phosphatase 2A. Endocr. 2005;146:5397-5406.
152. Foster JD, Cervinski MA, Gorentla BK, Vaughan RA. Regulation of the dopamine transporter by phosphorylation. Handb Exp Pharmacol. 2006;197-214.
153. Zahniser NR, Sorkin A. Trafficking of dopamine transporters in psychostimulant actions. Semin Cell Dev Biol. 2009;20:411-417.
154. Bulayeva NN, Watson CS. Xenoestrogen-induced ERK 1 and 2 activation via multiple membrane-initiated signaling pathways. Environ Health Perspect. 2004;112:1481-1487.
155. Narita SI, Goldblum RM, Watson CS, et al. Environmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators PMCID:17366818. Env Health Perspect. 2007;115:48-52.
156. Watson CS, Alyea RA, Jeng YJ, Kochukov MY. Nongenomic actions of low concentration estrogens and xenoestrogens on multiple tissues PMCID:17601655. Mol Cell Endocrinol. 2007;274:1-7.
157. Wozniak AL, Bulayeva NN, Watson CS. Xenoestrogens at picomolar to nanomolar concentrations trigger membrane estrogen receptor-a-mediated Ca2+ fluxes and prolactin release in GH3/B6 pituitary tumor cells. Environ Health Perspect. 2005;113: 431-439.
158. Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A. The estrogenic effect of bisphenol A disrupts pancreatic ß-cell function in vivo and induces insulin resistance. Environ Health Perspect. 2006;114:106-112.
159. Midoro-Horiuti T, Tiwari R, Watson CS, Goldblum RM. Maternal bisphenol a exposure promotes the development of experimental asthma in mouse pups. Environ Health Perspect. 2010;118:273-277.
160. McKinlay R, Plant JA, Bell JN, Voulvoulis N. Calculating human exposure to endocrine disrupting pesticides via agricultural and non-agricultural exposure routes. Sci Total Environ. 2008;398:1-12.
161. Hotchkiss AK, Rider CV, Blystone CR, et al. Fifteen years after "Wing-spread" - environmental endocrine disrupters and human and wildlife health: where we are today and where we need to go. Toxicol Sci. 2008;105:235-259.
162. Colborn T. Neurodevelopment and endocrine disruption. Environ Health Perspect. 2004;112:944-949.
163. Nadal A, Alonso-Magdalena P, Soriano S, Quesada I, Ropero AB. The pancreatic ß-cell as a target of estrogens and xenoestrogens: Implications for blood glucose homeostasis and diabetes. Mol Cell Endocrinol. 2009;304:63-68.
164. Krishnan AV, Stathis P, Permuth SF, Tokes L, Feldman D. Bisphenol A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Endocr. 1993;132:2279-2286.
165. Milligan SR, Balasubramanian AV, Kalita JC. Relative potency of xenobiotic estrogens in an acute in vivo mammalian assay. Environ Health Perspect. 1998;106:23-26.
166. vom Saal FS, Cooke PS, Buchanan DL, et al. A physiologically based approach to the study of bisphenol A and other estrogenic chemicals on the size of reproductive organs, daily sperm production, and behavior. Toxicol Ind Health. 1998;14:239-260.
167. Rudel RA, Camann DE, Spengler JD, Korn LR, Brody JG. Phthalates, alkylphenols, pesticides, polybrominated diphenyl ethers, and other endocrine-disrupting compounds in indoor air and dust. Environ Sci Technol. 2003;37:4543-4553.
168. Herbst AL. Behavior of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstilbestrol (DES). Gynecol Oncol. 2000;76:147-156.
169. Lakshmana MK, Raju TR. Endosulfan induces small but significant changes in the levels of noradrenaline, dopamine and serotonin in the developing rat brain and deficits in the operant learning performance. Toxicology. 1994;91:139-150.
170. Bornman MS, Pretorius E, Marx J, Smit E, van der Merwe CF. Ultrastructural effects of DDT, DDD, and DDE on neural cells of the chicken embryo model. Environ Toxicol. 2007;22:328-336.
171. Kitazawa M, Anantharam V, Kanthasamy AG. Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells. Free Radic Biol Med. 2001;31: 1473-1485.
172. Naqvi SM, Vaishnavi C. Bioaccumulative potential and toxicity of endosulfan insecticide to non-target animals. Comp Biochem Physiol C. 1993;105:347-361.
173. Otaka H, Yasuhara A, Morita M. Determination of bisphenol A and 4-nonylphenol in human milk using alkaline digestion and cleanup by solid-phase extraction. Anal Sci. 2003;19:1663-1666.
174. Sajiki J, Takahashi K, Yonekubo J. Sensitive method for the determination of bisphenol-A in serum using two systems of high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999;736:255-261.
175. Myers JP, vom Saal FS, Akingbemi BT, et al. Why public health agencies cannot depend on good laboratory practices as a criterion for selecting data: the case of bisphenol A. Environ Health Perspect. 2009;117:309-315.
176. Alonso-Magdalena P, Laribi O, Ropero AB, et al. Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic a-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans. Environ Health Perspect. 2005;113: 969-977.
177. Bulayeva NN, Watson CS. Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways. Environ Health Perspect. 2004;112:1481-1487.
178. Zsarnovszky A, Le HH, Wang HS, Belcher SM. Ontogeny of rapid estrogen-mediated extracellular signal-regulated kinase signaling in the rat cerebellar cortex: potent nongenomic agonist and endocrine disrupting activity of the xenoestrogen bisphenol A. Endocr. 2005;146:5388-5396.
179. Midoro-Horiuti T, Tiwari R, Watson CS, Goldblum RM. Maternal Bisphenol A exposure promotes the development of experimental asthma in mouse pups. Environ Health Perspect. 2010;118:273-277.
180. Della SD, Farabollini F, Dessi-Fulgheri F, Fusani L. Environmental-like exposure to low levels of estrogen affects sexual behavior and physiology of female rats. Endocrinology. 2008;149:5592-5598.
181. MacLusky NJ, Hajszan T, Leranth C. The environmental estrogen bisphenol a inhibits estradiol-induced hippocampal synaptogenesis. Environ Health Perspect. 2005;113:675-679.
182. Palanza P, Gioiosa L, vom Saal FS, Parmigiani S. Effects of developmental exposure to bisphenol A on brain and behavior in mice. Environ Res. 2008;108:150-157.
183. Zhou R, Zhang Z, Zhu Y, Chen L, Sokabe M, Chen L. Deficits in development of synaptic plasticity in rat dorsal striatum following prenatal and neonatal exposure to low-dose bisphenol A. Neuroscience. 2009;159:161-171.
184. Xu X, Liu Y, Sadamatsu M, et al. Perinatal bisphenol A affects the behavior and SRC-1 expression of male pups but does not influence on the thyroid hormone receptors and its responsive gene. Neurosci Res. 2007;58:149-155.
185. Fujimoto T, Kubo K, Aou S. Prenatal exposure to bisphenol A impairs sexual differentiation of exploratory behavior and increases depression-like behavior in rats. Brain Res. 2006;1068:49-55.
186. Negishi T, Kawasaki K, Suzaki S, et al. Behavioral alterations in response to fear-provoking stimuli and tranylcypromine induced by perinatal exposure to bisphenol A and nonylphenol in male rats. Environ Health Perspect. 2004;112:1159-1164.
187. Watson CS, Bulayeva NN, Wozniak AL, Alyea RA. Xenoestrogens are potent activators of nongenomic estrogenic responses. Steroids. 2007;72:124-134.
188. Suzuki T, Mizuo K, Nakazawa H, et al. Prenatal and neonatal exposure to bisphenol-a enhances the central dopamine d1 receptor-mediated action in mice: enhancement of the methamphetamine-induced abuse state. Neuroscience. 2003;117:639-644.
189. Miyatake M, Miyagawa K, Mizuo K, Narita M, Suzuki T. Dynamic changes in dopaminergic neurotransmission induced by a low concentration of bisphenol-A in neurones and astrocytes. J Neuroendocrinol. 2006;18:434-444.
190. Whitten PL, Patisaul HB. Cross-species and interassay comparisons of phytoestrogen action [Review]. Environ Health Perspect. 2001;109:5-20.
191. Adlercreutz H, Yamada T, Wahala K, Watanabe S. Maternal and neonatal phytoestrogens in Japanese women during birth. Am J Obstet Gynecol. 1999;180:737-743.
192. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hamalainen E. Estrogen metabolism and excretion in oriental and caucasian women. J Natl Cancer Inst. 1994;86:1076-1082.
193. Adlercreutz H. Phytoestrogens: epidemiology and a possible role in cancer protection. [Review]. Environ Health Perspect. 1995;103 Suppl 7: 103-112.
194. Kumar P, Padi SS, Naidu PS, Kumar A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol. 2006;17: 485-492.
195. Sonmez U, Sonmez A, Erbil G, Tekmen I, Baykara B. Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett. 2007;420:133-137.
196. Zhao L, Brinton RD. WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. Expert Rev Neurother. 2007; 7:1549-1564.
197. Whitten PL, Patisaul HB, Young LJ. Neurobehavioral actions of coumestrol and related isoflavonoids in rodents. Neurotoxicol Teratol. 2002;24:47-54.
198. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor ß. Endocr. 1998;139:4252-4263.
199. Harris DM, Besselink E, Henning SM, Go VLW, Heber D. Phytoestrogens Induce Differential Estrogen Receptor a-or ß-Mediated Responses in Transfected Breast Cancer Cells. Experimental Biology and Medicine. 2005;230:558-568.
200. Lephart ED, West TW, Weber KS, et al. Neurobehavioral effects of dietary soy phytoestrogens. Neurotoxicol Teratol. 2002;24:5-16.
201. Lund TD, Lephart ED. Dietary soy phytoestrogens produce anxiolytic effects in the elevated plus-maze. Brain Res. 2001;913:180-184.
202. Fernandez SP, Nguyen M, Yow TT, et al. The flavonoid glycosides, myricitrin, gossypin and naringin exert anxiolytic action in mice. Neurochem Res. 2009;34:1867-1875.
203. Garey J, Morgan MA, Frohlich J, McEwen BS, Pfaff DW. Effects of the phytoestrogen coumestrol on locomotor and fear-related behaviors in female mice. Horm Behav. 2001;40:65-76.
204. Paech K, Webb P, Kuiper GGJM, et al. Differential ligand activation of estrogen receptors ERa and ERb at AP1 sites. Science. 1997;227: 1508-1510.
205. Hall JM, McDonnell DP. The estrogen receptor ß-isoform (ERß) of the human estrogen receptor modulates ERa transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocr. 1999;140:5566-5578.
206. Lee YB, Lee HJ, Sohn HS. Soy isoflavones and cognitive function. J Nutr Biochem. 2005;16:641-649.
207. Sheehan DM. No-threshold dose-response curves for nongenotoxic chemicals: findings and applications for risk assessment. Environ Res. 2006;100:93-99.
208. Kochukov MY, Jeng YJ, Watson CS. Alkylphenol xenoestrogens with varying carbon chain lengths differentially and potently activate signaling and functional responses in GH3/B6/F10 somatomammotropes. Env Health Perspect. 2009;117:723-730.
209. Sheffler DJ, Conn PJ. Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells. Neuropharmacology. 2008;55:419-427.
210. Lipsett MB. Estrogen use and cancer risk. J Am Med Assoc. 1977;237: 1112-1115.
211. Crandall CJ, Guan M, Laughlin GA, et al. Increases in Serum Estrone Sulfate Level Are Associated with Increased Mammographic Density during Menopausal Hormone Therapy. Cancer Epidemiol Biomarkers Prev. 2008;17:1674-1681.
212. File SE, Heard JE, Rymer J. Trough oestradiol levels associated with cognitive impairment in post-menopausal women after 10 years of oestradiol implants. Psychopharmacology (Berl). 2002;161:107-112.
213. Maki PM. A systematic review of clinical trials of hormone therapy on cognitive function: effects of age at initiation and progestin use. Ann N Y Acad Sci. 2005;1052:182-197.
214. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol. 2005;162:404-414.
215. Krieger N, Lowy I, Aronowitz R, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health. 2005;59:740-748.
216. Barrett-Connor E, Laughlin GA. Endogenous and exogenous estrogen, cognitive function, and dementia in postmenopausal women: evidence from epidemiologic studies and clinical trials. Semin Reprod Med. 2009;27:275-282.
217. Laughlin GA, Kritz-Silverstein D, Barrett-Connor E. Endogenous oestrogens predict 4-year decline in verbal fluency in postmenopausal women: the Rancho Bernardo Study. Clin Endocrinol (Oxf). 2010;72:99-106.
218. Henderson VW. Aging, estrogens, and episodic memory in women. Cogn Behav Neurol. 2009;22:205-214.
219. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev. 2003;24:133-151.
220. Sherwin BB, Henry JF. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Front Neuroendocrinol. 2008;29:88-113.
221. Knuuti J, Kalliokoski R, Janatuinen T, et al. Effect of estradioldrospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Am J Cardiol. 2007;99:1648-1652.
222. Simpkins JW, Green PS, Gridley KE, Singh M, de Fiebre NC, Rajakumar G. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease. Am J Med. 1997;103:19S-25S.
223. Haynes LE, Lendon CL, Barber DJ, Mitchell IJ. 17 ß-oestradiol attenuates dexamethasone-induced lethal and sublethal neuronal damage in the striatum and hippocampus. Neuroscience. 2003;120:799-806.
224. Arvin M, Fedorkova L, Disshon KA, Dluzen DE, Leipheimer RE. Estrogen modulates responses of striatal dopamine neurons to MPP(+): evaluations using in vitro and in vivo techniques. Brain Res. 2000;872:160-171.
225. vom Saal FS, Hughes C. An extensive new literature concenring lowdose effects of bisphenol A shows the need for a new risk assessment. Environ Health Perspect. 2005;113:926-933.
226. Greenspan FS, Gardner DG. Appendix: Normal Hormone Reference Ranges. In: Greenspan FS, Gardner DG, editors. Basic and Clinical Endocrinology. 7th ed. New York: Lange Medical Books, McGraw Hill; 2004;925-926.
227. Katzenellenbogen BS, Bhardwaj B, Fang H, et al. Hormone binding and transcription activation by estrogen receptors: analyses using mammalian and yeast systems. J Steroid Biochem Mol Biol. 1993;47: 39-48.